



Article

Small-Molecule Inhibitors of the RNA m⁶A Demethylases FTO Potently Support the Survival of Dopamine Neurons

Simona Selberg ¹, Li-Ying Yu ², Olesja Bondarenko ², Esko Kankuri ³, Neinar Seli ⁴, Vera Kovaleva ², Koit Herodes ¹, Mart Saarma ² and Mati Karelson ^{1,*}

¹ Institute of Chemistry, University of Tartu, Ravila 14a, 50411 Tartu, Estonia; simona.selberg@ut.ee (S.S.); koit.herodes@ut.ee (K.H.)

² Institute of Biotechnology, HiLIFE, Viikinkaari 5D, University of Helsinki, 00014 Helsinki, Finland; li.yu@helsinki.fi (L.-Y.Y.); olesja.bondarenko@kbf.fi (O.B.); vera.kovaleva@helsinki.fi (V.K.); mart.saarma@helsinki.fi (M.S.)

³ Department of Pharmacology, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland; esko.kankuri@helsinki.fi

⁴ Chemestmed, Ltd., 50411 Tartu, Estonia; neinar@chemestmed.com

* Correspondence: mati.karelson@ut.ee

Abstract: The fat mass and obesity-associated protein (FTO), an RNA N⁶-methyladenosine (m⁶A) demethylase, is an important regulator of central nervous system development, neuronal signaling and disease. We present here the target-tailored development and biological characterization of small-molecule inhibitors of FTO. The active compounds were identified using high-throughput molecular docking and molecular dynamics screening of the ZINC compound library. In FTO binding and activity-inhibition assays the two best inhibitors demonstrated K_d = 185 nM; IC₅₀ = 1.46 μM (compound **2**) and K_d = 337 nM; IC₅₀ = 28.9 μM (compound **3**). Importantly, the treatment of mouse midbrain dopaminergic neurons with the compounds promoted cellular survival and rescued them from growth factor deprivation induced apoptosis already at nanomolar concentrations. Moreover, both the best inhibitors demonstrated good blood-brain-barrier penetration in the model system, 31.7% and 30.8%, respectively. The FTO inhibitors demonstrated increased potency as compared to our recently developed ALKBH5 m⁶A demethylase inhibitors in protecting dopamine neurons. Inhibition of m⁶A RNA demethylation by small-molecule drugs, as presented here, has therapeutic potential and provides tools for the identification of disease-modifying m⁶A RNAs in neurogenesis and neuroregeneration. Further refinement of the lead compounds identified in this study can also lead to unprecedented breakthroughs in the treatment of neurodegenerative diseases.

Keywords: FTO; ALKBH5; m⁶A; RNA; drug design; dopamine neurons



Citation: Selberg, S.; Yu, L.-Y.; Bondarenko, O.; Kankuri, E.; Seli, N.; Kovaleva, V.; Herodes, K.; Saarma, M.; Karelson, M. Small-Molecule Inhibitors of the RNA m⁶A Demethylases FTO Potently Support the Survival of Dopamine Neurons. *Int. J. Mol. Sci.* **2021**, *22*, 4537. <https://doi.org/10.3390/ijms22094537>

Academic Editor: Per Svenningsson

Received: 17 March 2021

Accepted: 22 April 2021

Published: 26 April 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Chemical modifications of RNA have a critical impact on many cellular functions, such as proliferation, survival, and differentiation [1,2]. In eukaryotic messenger RNA, the most abundant modification is N⁶-methyladenosine (m⁶A), which affects RNA splicing, intracellular transport, translation, and cytoplasmic degradation of RNA [3,4]. The levels of m⁶A in RNA are regulated by specific enzymes, methyltransferases and demethylases. These include m⁶A writers such as the methyltransferase-like protein 16 (METTL16) [5] as well as the RNA methyltransferase enzyme complex METTL3/METTL14/WTAP usually composed of three components: METTL3 (methyltransferase-like 3), METTL14 (methyltransferase-like 14) and WTAP (Wilm's tumor-1-associated protein) [6,7]. RNA m⁶A eraser enzymes include the RNA demethylases FTO (fat mass and obesity-associated protein) [8,9] and ALKBH5 (alkylation repair homolog protein 5) [10]. Additionally, the fate of RNA in post-transcriptional processes is determined by the m⁶A reader proteins that recognize specific m⁶A-modified RNA sequences and affect the stability, translation, and/or cellular localization of the transcript. Several RNA reader proteins have been identified [7,11], including three members

of YTH N⁶-Methyladenosine RNA Binding Protein (YTHDF)-family (YTHDF 1-3) and two members of the YTH domain-containing protein (YTHDC)-family (YTHDC1-2) [12]. Collectively, these three types of proteins coordinate the m⁶A RNA methylome and its fate in the eukaryotic cells.

RNA m⁶A modifications have been assigned key orchestrating roles in brain development, neuronal signaling and neurological disorders [13–18]. For example, m⁶A-dependent mRNA decay has been shown to be critical for proper transcriptional pre-patterning in mammalian cortical neurogenesis [19]. Weng et al. demonstrated that axonal injury-induced m⁶A methylation and downstream signaling enhances the synthesis of regeneration-associated proteins essential for functional axon regeneration of peripheral sensory neurons [20]. Moreover, it has been shown that genes associated with m⁶A control may play a role in conferring risk of dementia [21]. However, because the homeostasis of RNA m⁶A methylation in neurons is controlled on multiple levels, unselective or global modification of m⁶A levels can yield contradictory results. For example, through the actions of the reader protein YTHDF1, m⁶A residues have been shown to directly facilitate adaptive processes such as learning and memory in the adult mouse hippocampus [22]. Deficiency of the m⁶A eraser FTO has been demonstrated to lead to impaired learning and memory through reduced proliferation and neuronal differentiation of adult neural stem cells in FTO full-knockout mice [23]. In addition, conventional and dopamine (DA) neuron-specific Fto gene knockout mice show impaired DA receptor type 2 (D2R)- and type 3 (D3R)-dependent control of neuronal activity and behavioral responses [24]. Treatment of PC12 cells derived from a pheochromocytoma of the rat adrenal medulla in vitro as well as the rat striatum in vivo with the 6-OHDA neurotoxin in a rat model of Parkinson's disease (PD) results in a global reduction of the m⁶A residues in mRNAs [25]. Reduction of m⁶A levels in pheochromocytoma PC12 cells by treatment with the non-selective nucleoside methylation inhibitor, cycloleucine, or alternatively by FTO overexpression induced apoptotic cell death through increased expression of N-methyl-D-aspartate (NMDA) receptor 1, oxidative stress and Ca²⁺ influx [25]. However, these results do not directly demonstrate the dysregulation of m⁶A in dopamine neurons. However, because the striatum contains the fibers of dopamine neurons, it is possible that the dysregulation of m⁶A is related to neurodegeneration in PD. Available data indicate that either the compensatory upregulation or downregulation of m⁶A could be needed in neuronal cells, depending on their physiological or pathological state. However, the precise role of the RNA demethylases FTO and ALKBH5 in the regulation of survival and regeneration of DA neurons has remained enigmatic. One reason for this is the lack of highly specific inhibitors of these enzymes. As shown in the rat 6-OHDA PD model, the downregulation of m⁶A in the striatum occurs in parallel with the axonal degeneration and DA neuron death [25]. Therefore, it is logical to hypothesize that inhibitors of the RNA m⁶A demethylases FTO or ALKBH5 that increase the m⁶A methylation level of mRNA should support the homeostasis of m⁶A in DA neurons and their survival under stress. Only a very limited number of FTO inhibitors are presently known, mostly of a non-specific nature [26–31].

We used in silico-based rational target-tailored development of small-molecule FTO inhibitors and determined their binding affinity, kinetics, and their effect on enzymatic functions experimentally. We identified unique small-molecule ligands that bind to FTO and very potently inhibit its enzymatic activity. In particular, two of these FTO inhibitors, already at 10 nM concentration, supported the survival of growth factor-deprived primary DA neurons in culture. Two ALKBH5 inhibitors that we have described earlier [32], were less potent in rescuing DA neurons. This is the first demonstration that inhibitors of FTO, and in general m⁶A regulators can support the survival and protect dopamine neurons from growth factor deprivation induced death in vitro. These compounds may further serve as lead molecules for development of novel drugs for neurodegenerative diseases such as PD.

2. Results and Discussion

2.1. Computational Modeling of FTO Ligand Binding Site and Virtual Screening

The regions of probable interactions between a ligand and FTO protein were found by carrying out the molecular docking using AutoDock 4.1. As shown by the molecular docking calculations, the amino acid residues of the protein Asp233, Tyr106, Glu234, Arg96, and Arg322 were involved in specific interactions between the protein and ligand (Figure 1).




Figure 1. Docking modeling FTO binding sites of the inhibitors: (a) compound 2, 4-amino-8-chloroquinoline-3-carboxylic acid and (b) compound 3, 8-aminoquinoline-3-carboxylic acid.

A virtual screening on ZINC compound library [33] was carried out using the best known FTO inhibitors from the ChemBL database [34] as templates (Figure 2). The docking free energies ΔG and ligand efficiencies LE of the best binding compounds are given and their molecular structures are given in Table 1.











Figure 2. A set of the known FTO inhibitors used as templates in high-throughput virtual docking screening.

Table 1. Compounds with the highest docking efficiencies DE to FTO protein.

No.	Compound Structure	ΔG (kcal/mol)	DE
<u>1</u>		-7.37	0.53
<u>2</u>		-7.70	0.51
<u>3</u>		-7.03	0.50
<u>4</u>		-8.78	0.49
<u>5</u>		-7.17	0.48
<u>6</u>		-9.45	0.47
<u>7</u> *		-6.53	0.44
<u>8</u> *		-4.78	0.32

* ALKBH5 inhibitor.

The molecular dynamics simulations were carried out for two compounds, the compounds with the best enzymatic inhibition activity (**2** and **3**). In the case of compound **2**, several molecular dynamics simulation runs were carried out with the length of 10 ns. This system was stable throughout the calculation time (Figure 3a). A very strong hydrogen bond is detected between the pyridine nitrogen atom of the ligand and the ammonium group of Arg96 residue of the FTO protein (Figure 3b). The simulation interactions diagram (Figure 3c) indicates that the most important interactions for this compound are hydrogen bonds between ligand and residues Arg96, Glu234, Arg322, and Asp233 of FTO. Furthermore, there are additional hydrophobic interactions between ligand **2** and FTO protein. The bars in diagram Figure 3c characterize the time fraction that a particular specific interaction is maintained during the simulation. Based on this, we can assume that the compound **2** is bound to tight specific pocket at the active site of FTO protein (Figure 3d) [35].




Figure 3. Results of the molecular dynamics simulation of the FTO complex with compound **2**. (a) The protein and ligand position root mean square deviation (RMSD) plot against time in the case of the FTO complex with compound **2** for a representative 10 ns run. (b) Desmond 2D profile data for the compound **2** binding to FTO protein. (c) Normalized stacked bar chart representation of interactions and contacts over the course of trajectory (values over 1.0 are possible as some residues make multiple contacts of same subtype with ligands); interactions occurring more than 50% of the simulation time. Interaction diagram between the compound **2** and FTO protein. (d) The position of the compound **2** in the structure of FTO, related to Figure 1a.

The results of the molecular dynamics simulation of compound **3** are summarized in Figure 4. Again, five molecular dynamics simulation runs were carried out with the length of 10 ns, and the trajectory analysis shows the stability of the system during the calculation (Figure 4a). The results indicate the presence of hydrogen bonds between the ligand carbonyl group of compound **3** and Glu234 and Asp233 of the FTO protein. In addition, a water bridge with Arg96 and salt bridge with Arg322 (Figure 4b) is suggested. The simulation interactions diagram (Figure 4c) reveals a very stable hydrogen bonding

(Asp233 and Glu234) and several ionic bridges (His231, Asp233, His307, and Arg322) and water bridges (Arg96, Ser229, and Arg322) between the compound **3** and protein. The compound is bound to tight specific pocket at the active site of FTO protein (Figure 4d).




Figure 4. Results of the molecular dynamics simulation of the FTO complex with compound **3**. (a) The protein and ligand position root mean square deviation (RMSD) plot against time in the case of the FTO complex with compound **3** for a representative 10 ns run. (b) Desmond 2D profile data for the compound **3** binding to FTO protein. (c) Normalized stacked bar chart representation of interactions and contacts over the course of trajectory (values over 1.0 are possible as some residues make multiple contacts of same subtype with ligands); interactions occurring more than 50% of the simulation time. Interaction diagram between the compound **3** and FTO protein. (d) The position of the compound **3** in the structure of FTO, related to Figure 1b.

2.2. Enzyme Activity Inhibition

The enzyme inhibition measurements were carried out for the predicted FTO strongly bound compounds **1–6**. A significant concentration-dependent inhibitory effect was observed for quinolone derivatives **2** and **3** (Figure 5). The inhibitory concentrations were $IC_{50} = 1.46 \mu\text{M}$ for compound **2** and $IC_{50} = 28.9 \mu\text{M}$ for compound **3**. No significant inhibitory effect was noticed for the other three predicted compounds (**1**, **4**, **5**, and **6**) up to the $100 \mu\text{M}$ concentration.

2.3. Protein Binding of Compounds

Furthermore, we studied the binding of the two active inhibitors **2** and **3** to the FTO protein using MST. Both compounds are binding at sub-micromolar concentrations. The protein binding K_d values $K_d = 185 \pm 77 \text{ nM}$ for compound **2** and $K_d = 337 \pm 184 \text{ nM}$ for compound **3** (Figure 6) are in good agreement with the respective enzymatic inhibition IC_{50} values for these compounds.




Figure 5. Inhibitory effect of the compounds **2** (a) and **3** (b) on the demethylation of the probe RNA by FTO. Response reflects the m⁶A level in probe.




Figure 6. Two inhibitors directly interact with FTO protein as shown by microscale thermophoresis. (a) Unlabeled titrated compound **2** (0–10 μM) interacts with Alexa647-labeled through His-tag FTO (20 nM). (b) Unlabeled titrated compound **3** (0–10 μM) interacts with Alexa647-labeled through His-tag FTO (20 nM). For (a,b) microscale thermophoresis binding curves, showing fraction bound values from $n = 3$ individual repeats per binding pair \pm SEM, K_d values \pm error estimations are indicated.

2.4. Neuronal Survival Experiments

To our knowledge, the direct effect of FTO and ALKBH5 inhibitors has never been tested on DA neurons. Earlier data demonstrate that reduced m⁶A levels in 6-OHDA-treated tyrosine hydroxylase-expressing rat pheochromocytoma PC12 cells having some similarity to peripheral sympathetic neurons by overexpressing FTO result in apoptosis [25]. We therefore hypothesized that the inhibition of RNA m⁶A demethylases in DA neurons could counteract this apoptotic process and support the survival of dopamine neurons. To test this hypothesis, we carried out a study on the influence of the developed FTO inhibitors on the survival of mouse midbrain dopamine neurons after inducing their apoptosis by

growth factor deprivation [36–38]. This model has some limitations, as embryonic rodent neurons are used and the growth factor deprivation or neurotoxin poisoning do not replicate the real pathological situation in Parkinson's disease. Nevertheless, it is a widely used cellular model to test the efficacy of growth factors and small molecules before testing them in animal models of Parkinson's disease [39,40]. It has been demonstrated that the preferred cellular substrate for FTO is not the m⁶A but its further modification N^{6,2'}-O-dimethyladenosine (m⁶Am), which is exclusively found adjacent to the 7-methylguanine (m⁷G) cap in mRNA [41–43]. Furthermore, FTO is primarily, and potentially exclusively localized in the nucleus [8,44]. Thus, the presently known main m⁶A demethylating enzyme is the ALKB Homolog 5 (ALKBH5), belonging to the non-heme Fe^(II) and α -KG-dependent dioxygenase ALKB family of proteins. Contrasting FTO, ALKBH5 has no activity towards m⁶Am and appears to be localized to nuclear speckles [9]. There may be also a significant difference in the target RNAs. In the case of FTO, the main target RNA may not be mRNA, but snRNA [42].

Since mRNA and snRNA m⁶A modification may have impact on neuronal survival, it was therefore interesting to compare the effects of inhibition of these two RNA m⁶A demethylases on the survival of dopamine neurons in the in vitro model of Parkinson's disease. Thus, the experiments were carried out not only with two FTO inhibitors developed in this study, compounds **2** and **3**, but also with two our recently reported ALKBH5 inhibitors, 2-[(1-hydroxy-2-oxo-2-phenylethyl)sulfanyl]acetic acid **7** and 4-[[furan-2-yl)methyl]amino]-1,2-diazinane-3,6-dione **8**. The inhibitory concentrations against ALKBH5 are IC₅₀ = 0.840 μ M for the compound **7** and IC₅₀ = 1.79 μ M for the compound **8**, respectively [32].

GDNF has been shown to protect cultured embryonic dopamine neurons from growth factor deprivation induced apoptosis, as well as 6-OHDA-induced cell death in vitro and in vivo [38,40]. We, therefore, assessed the neuroprotective ability of different concentrations of FTO or ALKBH5 inhibitors in cultured growth factor deprived dopamine neurons. Human recombinant GDNF (100 ng/mL) or a condition without any neurotrophic compound added were used as positive and negative controls, respectively. Growth factor deprivation caused cell death by 50–70%. The results expressed as % of cell survival compared to GDNF-maintained neurons for the FTO inhibitors are presented in Figure 7A. Representative images of mouse E13 wild-type midbrain cultures treated with vehicle, FTO or ALKBH5 inhibitors, and GDNF (positive control) probed with anti-TH antibody are shown on Figure 7B. Both FTO inhibitors **2** and **3** similarly to GDNF dose-dependently protected embryonic midbrain dopamine neurons in culture from growth factor deprivation-induced cell death. Both FTO inhibitors can also rescue dopamine neurons from 6-OHDA induced neuronal cell death (data not shown). A neuroprotective effect can be seen already at 10 nM, and statistically significant outcome is observed at the concentration 100 nM and 1000 nM concentrations of both the inhibitors **2** and **3**. Hence, the inhibition of the m⁶A demethylase FTO promotes on the survival of dopamine neurons and rescues them in growth factor deprivation in vitro model of apoptosis without any signs of toxicity of the tested compounds.

Similarly, in growth factor deprivation model, ALKBH5 inhibitors **7** and **8** at three tested concentrations increased the number of TH-positive neurons (Figure 7). Compound **8** rescued growth factor deprivation challenged dopamine neurons at 10 nM and at 1000 nM, but showed only a trend at 100 nM. Compound **7** on the other hand showed only trend in the neuroprotection of apoptosis induced E13 dopamine neurons.

It is interesting to note that the potency of FTO inhibitors **2** and **3** in protecting and rescuing DA neurons in vitro is comparable to that of GDNF. Since GDNF, when directly injected into the midbrain, protects dopamine neurons also in animal models of PD [40,45], it is logical to assume that FTO and ALKBH5 inhibitors can also be neuroprotective in vivo. The main limitation in the clinical use of GDNF and other neurotrophic proteins in the treatment of PD is their inability to pass through the blood–brain barrier (BBB). As the first step towards in vivo testing of the neuroprotective activities of FTO inhibitors we assessed their ability to penetrate through the artificial BBB. Since FTO and ALKBH5 are expressed

in addition to dopamine neurons also in many other types of neurons it is logical to assume that FTO and ALKBH5 inhibitors described in this study can support their survival as well. Further studies are needed to test this hypothesis.




Figure 7. Effect of the FTO inhibitors 2 and 3 and ALKBH5 inhibitors 7 and 8 on the survival of the dopamine neurons. **(A)** The number of TH-positive cells in the wild-type midbrain cultures with growth factor deprivation and treated with vehicle, FTO inhibitors 2 and 3 and ALKBH5 inhibitors 7 and 8 or GDNF normalized to the total number of cells in the culture and presented as percentage of vehicle treated samples, average from 4–5 well from one experiment. Both experiments were repeated three times with reproducible results. Concentration of GDNF used as a positive control is 3 nM (100 ng/mL) and concentration of inhibitors are in nM. No factor—Vehicle. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, one-way ANOVA with Dunnett's posthoc test. **(B)** Representative images of immunoreactivity for the dopaminergic neuronal marker TH at DIV 5. Scale bars: 1 mm.

2.5. Penetration of the FTO Inhibitors Through the Blood-Brain Barrier in Artificial In Vitro Model

The effects of FTO inhibitors were studied in the artificial in vitro BBB model, where murine endothelial cells bEnd3 were co-cultured with murine HIF1 α astrocytes on hanging cell culture inserts. The BBB penetration % defined as the ratio of the concentration of the compound in the well ('brain') side and the concentration in the insert, were $31.7 \pm 3.3\%$ for compound **2** and $30.8 \pm 1.9\%$ for compound **3**. Therefore, both compounds exhibit good penetration ability.

3. Materials and Methods

3.1. Compounds

4-aminoquinoline-3-carboxylic acid (**1**); Vitas M Chemical Limited, Causeway Bay, Hong Kong, China, Cat. No. STK660776, Purity: >90%.

4-amino-8-chloroquinoline-3-carboxylic acid (**2**); Vitas M Chemical Limited, Causeway Bay, Hong Kong, China, Cat. No. STK787835, Purity: >90%.

8-aminoquinoline-3-carboxylic acid (**3**); Ark Pharm Inc., Arlington Heights, IL, USA, Cat. No. AK200350, Purity: 98%.

(2E)-4-[(3-methylphenyl)formohydrazido]-4-oxobut-2-enoic acid (**4**); Vitas M Chemical Limited, Causeway Bay, Hong Kong, China, Cat. No. STK120795, Purity: >90%.

8-hydroxyquinoline-5-carboxylic acid (**5**); Enamine Ltd., Monmouth Jct., NJ, US, Cat. No. Z233564176, Purity: >90%.

3-methyl-N'-(3-methylbenzoyl)benzohydrazide (**6**); Vitas M Chemical Limited, Causeway Bay, Hong Kong, China, Cat. No. STK087016, Purity: >90%.

2-[(1-hydroxy-2-oxo-2-phenylethyl)sulfanyl]acetic acid (**7**); Enamine Ltd., Monmouth Jct., NJ, US, Cat. No. EN300-14040, Purity: >90%.

4-[[furan-2-yl)methyl]amino]-1,2-diazinane-3,6-dione (**8**); Vitas M Chemical Limited, Causeway Bay, Hong Kong, China, Cat. No. STL352808, Purity: >90%.

3.2. FTO Protein

FTO protein was provided by ProteoGenics SAS (Schiltigheim, France, www.ProteoGenix.science.com accessed on 25 April 2021). The details of the protein synthesis are given in Supplementary Material. This includes the map of the vector for FTO-6His protein (Figure S1), the protein expression test (Figure S2) and the protein purification test (Figure S3). The purity of the FTO protein was >90%.

3.3. Computational Modeling

The crystal structure of the FTO in complex with 5-carboxy-8-hydroxyquinoline IOX1 (pdb:4IE4) [27] was chosen for the prediction of potential efficient ligands using molecular docking modeling. The ligand IOX1 was removed from the complex in order to proceed with the search of novel ligands. The catalytic center of the protein involves a bivalent transition metal ion, either Mn²⁺, Fe²⁺, Ni²⁺, or Zn²⁺. In our molecular docking simulations Zn²⁺ was used. The raw crystal structure was corrected and hydrogen atoms were automatically added to the protein using Schrödinger's Protein Preparation Wizard of Maestro 10.7, (Schrödinger, Inc., New York, NY, USA) [46]. AutoDock 4.2 (The Scripps Research Institute, La Jolla, CA, USA) [47] was used for the docking studies to find out binding modes and binding energies of ligands to the receptor. The number of rotatable bonds of ligand was set by default by AutoDock Tools 1.5.6 (The Scripps Research Institute, La Jolla, CA, USA). However, if the number was greater than 6, then some of rotatable bonds were made as non-rotatable, otherwise calculations can be inaccurate. The active site was surrounded with a grid-box sized 80 × 80 × 80 points with spacing of 0.375 Å. The AutoDock 4.2 force field was used in all molecular docking simulations. The docking efficiencies (DE) were calculated as

$$DE = \frac{\Delta G_{dock}}{N} \quad (1)$$

where ΔG_{dock} is the docking free energy and N —the number of non-hydrogen (“heavy”) atoms in the ligand molecule.

The structures of ligand molecules were optimized using the density functional theory B3LYP method [48] with 6–31G basis set.

The molecular dynamics simulations were carried out using Desmond simulation package of Schrödinger LLC [49]. The NPT ensemble with the temperature 300 K and pressure 1 bar was applied in all runs. Five simulation runs with the length 10 ns and with relaxation time 1 ps were carried out for each system. The OPLS_2005 force field parameters were used in all simulations [50]. The long-range electrostatic interactions were calculated using the Particle Mesh Ewald method [51]. The cutoff radius in Coloumb interactions was 9.0 Å. The water molecules were described using the simple point charge (SPC) model [52]. The types of physical interactions between the ligands and enzyme were analyzed using the simulation interaction diagram tool implemented in Desmond molecular dynamics package. The stability of molecular dynamics simulations was monitored by looking on the root mean square deviation (RMSD) of the ligand and protein atom positions in time.

3.4. Protein Binding Study Using Microscale Thermophoresis

The microscale thermophoresis (MST) experiments were performed using Monolith NT.115 instrument (NanoTemper Technologies GmbH, Germany). Recombinant human FTO protein was labeled through His-tag using Monolith His-Tag Labeling Kit RED-tris-NTA (NanoTemper Technologies GmbH; MO-L008). The labelled FTO protein (target) was used at 20 nM in all the experiments and 10 μ M starting concentrations of ligands FTO inhibitors **2** or **3** were used in both series of experiments.

The measurements were done in a buffer containing 10 mM Na-phosphate buffer, pH 7.4, 1 mM $MgCl_2$, 3 mM KCl, 150 mM NaCl, 0.05% Tween-20 in premium coated capillaries (NanoTemper Technologies GmbH; MO-K025) using red LED source, power set at 100% and medium MST power at 25 °C. Each data point represents mean fraction bound values from $n = 3$ independent experiments per binding pair \pm S.D, K_d values \pm error estimations are indicated. Data analysis was performed using MO.Affinity Analysis v2.3 software.

3.5. Enzyme Inhibition Assay

The enzymatic assay was modified from Huang et al. [29] The experiments were conducted in reaction buffer (50 mM Tris-HCl, pH 7.5, 300 μ M 2OG, 280 μ M $(NH_4)_2Fe(SO_4)_2$, and 2 mM L-ascorbic acid). The reaction mixture contained 200 ng methylated N^6 -adenine RNA probe (SEQ ID NO: 1) (5'-CUUGUCAm6ACAGCAGA-3', Dharmacon, Lafayette, CO, USA) and 10 nM FTO protein and different concentrations of ligands (1 nM to 100 μ M). Reactions were incubated on 96-well plate for 2 h at RT. After that, the amount of m^6A that was measured using EpiQuik m^6A RNA methylation Quantification Colorimetric Kit (Epigentek, Farmingdale, NY, USA).

The inhibitory effect IE of compounds on RNA probe demethylation by FTO was calculated as the enhancement of the m^6A amount as compared to the negative control (DMSO) relative to the difference between m^6A amounts of the positive control (max inhibition) and the negative control (Equation (2))

$$IE = \frac{C_{inh} - C_{DMSO}}{C_{inh(max)} - C_{DMSO}} \quad (2)$$

where C_{inh} , $C_{inh(max)}$, and C_{DMSO} are the amounts of m^6A at a given concentration of the inhibitor, maximum inhibition and in the case of DMSO, respectively.

3.6. Primary Cultures of Midbrain Dopamine Neurons and m^6A Regulator Treatment

The midbrain floors were dissected from the ventral mesencephalic of 13 days old NMRI strain mouse embryos following the published procedure [38]. The tissues were incubated with 0.5% trypsin (103139, MP Biomedicals, Inc, Thermo Fisher Scientific, Waltham, MA, USA) in HBSS (Ca^{2+}/Mg^{2+} -free) (14170112, Invitrogen, Thermo Fisher Scientific,

Carlsbad, CA, USA) for 20 min at 37 °C, then mechanically dissociated. Cells were plated onto the 96-well plates coated with poly-L-ornithine (Sigma-Aldrich, Merck KGaA, St. Louis, MO, USA). Equal volumes of cell suspension were plated onto the center of the dish. The dopamine neurons were cultured for five DIV in presence of cell culture media Dulbecco's MEM/Nut mix F12 (Invitrogen/Gibco; 21331-020), 100 × N2 serum supplement (Invitrogen/ Gibco; 17502-048), 33 mM D-Glucose (Sigma; G-8769), 0.5 mM L-Glutamine (Invitrogen/ Gibco; 25030-032), and 100 µg/mL Primocin (Invivo Gen, San Diego, CA, USA)]. On 6 DIV, to deprive growth factors, the cultures were washed three times with normal medium and the FTO and ALKBH5 inhibitors and glial cell line-derived neurotrophic factor (GDNF) were applied [38]. The cells were grown for five days with different concentrations of FTO and ALKBH5 inhibitors. Human recombinant GDNF (100 ng/mL) (Icosagen AS, Tartu, Estonia) or a condition without any neurotrophic compound added were used as positive and negative controls, respectively.

After growing five days, the neuronal cultures were fixed and stained with anti-Tyrosine Hydroxylase antibody (MAB318, Millipore Bioscience Research Reagents, Temecula, CA, USA). Images were acquired by CellInsight (Thermo Fisher Scientific) high-content imaging equipment. Immunopositive neurons were counted by CellProfiler software and the data was analyzed by CellProfiler analyst software [53]. The results are expressed as % of cell survival compared to GDNF-maintained neurons [54].

All animal experiments were carried out following European Community guidelines for the use of experimental animals and approved by the Finnish National Experiment Board (License number: ESAVI/12830/2020) and also by the Laboratory Animal Center of the University of Helsinki (license no. KEK20-015; 2.7.2020).

3.7. Artificial Blood–Brain Barrier Model

Artificial in vitro blood–brain barrier (BBB) was established as described by Le Joncour et al. [55] Murine endothelial cells bEnd3 (ATCC CRL-2299) were co-cultured with murine hypoxia-inducible factor knock out (HIFko) astrocytes (passage 12, received from Le Joncour) on hanging cell culture inserts (BD Falcon 353091, Franklin Lakes, NJ, USA) for five days in fetal bovine serum (FBS)-free conditions. 2.5 mL of FTO inhibitors (final concentration of 10 µM) were added into the insert (representing the 'blood' side) of the BBB cell. After 1 h incubation, 1 mL of the sample was taken from the insert and from the well ('brain' side), and the concentration of the compounds was measured by high-performance liquid chromatography (HPLC). Penetration % was defined by dividing the concentration of the compound in the well compared to the concentration in the insert. The concentration of the studied compounds is each side of the BBB cell were analyzed using LC-MS system consisting of Agilent 1290 UHPLC (Agilent, Inc., Santa Clara, CA, USA) and Agilent 6460 Triple Quadrupole MS (Agilent, Inc., Santa Clara, CA 95051, USA). Chromatographic separation was carried out on XBridge Shield RP18 3.5 µm, 3.0 × 150 mm (Waters Corporation, 34 Maple Street, Milford, MA, USA) column using 5 mM aqueous ammonium acetate (pH adjusted to 5.13 with formic acid) and methanol as eluent components. Linear gradient from 3% to 50% methanol in 12 min followed by 5 min isocratic segment. Eluent flow rate was 0.3 mL/min and sample injection volume was 2 µL. Electrospray ion source (Agilent Jet Stream, Agilent, Inc., Santa Clara, CA 95051, USA) was operated in positive ionization mode using default values for gas flows, temperatures, and potentials. For each compound one transition was selected and respective collision energies coarsely optimized.

3.8. Quantification and Statistical Analysis

Enzymatic assay curve-fitting analysis and determination of the IC₅₀ and EC₅₀ values were performed using AAT Bioquest, Inc. Quest Graph™ IC₅₀ Calculator (v.1, Sunnyvale, CA, USA). MST data analysis was performed using MO.Affinity Analysis v2.3 software (NanoTemper Technologies GmbH, Munich, Germany). Statistical significance in cell survival experiments was assessed using one-way ANOVA and unpaired *t*-test with

the GraphPad Prism8 software (GraphPad Software, Inc., 2365 Northside Dr., Suite 560, San Diego, CA, USA). Results were considered statistically significant at p values lower than 0.05.

4. Conclusions

The m⁶A RNA modifications and their dynamics in the cell has been recently related to numerous cell developmental, physiological and pathological processes, including neurogenesis and neuronal survival. Here we demonstrated that the inhibition of the m⁶A demethylation by inhibiting FTO or ALKBH5, that supposedly takes place predominantly in the cell nucleus supports the survival of the dopamine neurons and protects them from growth factor deprivation-induced apoptosis. The neuroprotective efficacy of two FTO inhibitors in this in vitro model of PD is similar to that of GDNF. Since both neuroprotective FTO inhibitors have the effect on the permeability of artificial BBB in vitro, it is of great interest to test their activity in animal models of PD in future studies. Differently from GDNF, these compounds have the potential to penetrate the BBB, so they can potentially be delivered systemically avoiding risky and complicated brain surgery. It has been demonstrated earlier that the substrate RNA targets for the two RNA m⁶A demethylases, FTO and ALKBH5 are different, m⁶Am and m⁶A, respectively. Therefore, it is exciting to observe a very similar (although of different intensity) effects by the inhibitors of both these enzymes on the dopamine neuron survival. The dopamine neurons have complicated neurite network with extensive number of synaptic contacts that require very demanding intracellular RNA transport and mRNA translation. Further studies in order to identify these specific RNA targets in neuronal cells could give new basic information about the neurogenesis and neuroregeneration. Another important outcome of the present study is the demonstration of possibility to employ a completely new type of neuroprotective compounds, the small-molecule RNA m⁶A demethylase inhibitors for the further development of drugs against Parkinson's and possibly Alzheimer's diseases, amyotrophic lateral sclerosis, and other neurodegenerative disorders.

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/ijms22094537/s1>.

Author Contributions: S.S. computational modeling, virtual screening, enzyme inhibition experiments, data analysis; L.-Y.Y. neuronal survival experiments; O.B. and K.H. BBB measurements; V.K. MST binding experiments; M.S. design and data analysis of neuronal survival and MST experiments; N.S. funding acquisition and data analysis; M.K. conceptualization and coordination of the study, data analysis; M.K., M.S., S.S., E.K., and V.K. writing and editing manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Chemestmed, Ltd., Riia tn 130b/2, Tartu 50411, Estonia.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (protocol code KEK15-022, 2.7.2020).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Song, J.; Yi, C. Chemical Modifications to RNA: A New Layer of Gene Expression Regulation. *ACS Chem. Biol.* **2017**, *12*, 316–325. [[CrossRef](#)]
2. Tzelepis, K.; Rausch, O.; Kouzarides, T. RNA-Modifying Enzymes and Their Function in a Chromatin Context. *Nat. Struct. Mol. Biol.* **2019**, *26*, 858–862. [[CrossRef](#)]
3. Maity, A.; Das, B. N⁶-Methyladenosine Modification in MRNA: Machinery, Function and Implications for Health and Diseases. *FEBS J.* **2016**, *283*, 1607–1630. [[CrossRef](#)]

4. Roundtree, I.A.; Evans, M.E.; Pan, T.; He, C. Dynamic RNA Modifications in Gene Expression Regulation. *Cell* **2017**, *169*, 1187–1200. [[CrossRef](#)] [[PubMed](#)]
5. Brown, J.A.; Kinzig, C.G.; DeGregorio, S.J.; Steitz, J.A. Methyltransferase-like Protein 16 Binds the 3'-Terminal Triple Helix of MALAT1 Long Noncoding RNA. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 14013–14018. [[CrossRef](#)]
6. Liu, J.; Yue, Y.; Han, D.; Wang, X.; Fu, Y.; Zhang, L.; Jia, G.; Yu, M.; Lu, Z.; Deng, X.; et al. A METTL3–METTL14 Complex Mediates Mammalian Nuclear RNA N⁶-Adenosine Methylation. *Nat. Chem. Biol.* **2014**, *10*, 93–95. [[CrossRef](#)] [[PubMed](#)]
7. Meyer, K.D.; Jaffrey, S.R. Rethinking M6A Readers, Writers, and Erasers. *Annu. Rev. Cell Dev. Biol.* **2017**, *33*, 319–342. [[CrossRef](#)]
8. Jia, G.; Fu, Y.; Zhao, X.; Dai, Q.; Zheng, G.; Yang, Y.; Yi, C.; Lindahl, T.; Pan, T.; Yang, Y.-G.; et al. N⁶-Methyladenosine in Nuclear RNA Is a Major Substrate of the Obesity-Associated FTO. *Nat. Chem. Biol.* **2011**, *7*, 885–887. [[CrossRef](#)]
9. Zheng, G.; Dahl, J.A.; Niu, Y.; Fedorcsak, P.; Huang, C.-M.; Li, C.J.; Vågbo, C.B.; Shi, Y.; Wang, W.-L.; Song, S.-H.; et al. ALKBH5 Is a Mammalian RNA Demethylase That Impacts RNA Metabolism and Mouse Fertility. *Mol. Cell* **2013**, *49*, 18–29. [[CrossRef](#)] [[PubMed](#)]
10. Wang, J.; Wang, J.; Gu, Q.; Ma, Y.; Yang, Y.; Zhu, J.; Zhang, Q. The Biological Function of M6A Demethylase ALKBH5 and Its Role in Human Disease. *Cancer Cell Int.* **2020**, *20*, 347. [[CrossRef](#)]
11. Patil, D.P.; Pickering, B.F.; Jaffrey, S.R. Reading M6A in the Transcriptome: M6A-Binding Proteins. *Trends Cell Biol.* **2018**, *28*, 113–127. [[CrossRef](#)]
12. Wojtas, M.N.; Pandey, R.R.; Mendel, M.; Homolka, D.; Sachidanandam, R.; Pillai, R.S. Regulation of M6A Transcripts by the 3'→5' RNA Helicase YTHDC2 Is Essential for a Successful Meiotic Program in the Mammalian Germline. *Mol. Cell* **2017**, *68*, 374–387.e12. [[CrossRef](#)]
13. Angelova, M.T.; Dimitrova, D.G.; Dinges, N.; Lence, T.; Worpenberg, L.; Carré, C.; Roignant, J.-Y. The Emerging Field of Epitranscriptomics in Neurodevelopmental and Neuronal Disorders. *Front. Bioeng. Biotechnol.* **2018**, *6*. [[CrossRef](#)] [[PubMed](#)]
14. Jung, Y.; Goldman, D. Role of RNA Modifications in Brain and Behavior. *Genes Brain Behav.* **2018**, *17*, e12444. [[CrossRef](#)]
15. Noack, F.; Calegari, F. Epitranscriptomics: A New Regulatory Mechanism of Brain Development and Function. *Front. Neurosci.* **2018**, *12*. [[CrossRef](#)] [[PubMed](#)]
16. Widagdo, J.; Anggono, V. The M6A-Epitranscriptomic Signature in Neurobiology: From Neurodevelopment to Brain Plasticity. *J. Neurochem.* **2018**, *147*, 137–152. [[CrossRef](#)]
17. Du, K.; Zhang, L.; Lee, T.; Sun, T. M6A RNA Methylation Controls Neural Development and Is Involved in Human Diseases. *Mol. Neurobiol.* **2019**, *56*, 1596–1606. [[CrossRef](#)] [[PubMed](#)]
18. Livneh, I.; Moshitch-Moshkovitz, S.; Amariglio, N.; Rechavi, G.; Dominissini, D. The m⁶A Epitranscriptome: Transcriptome Plasticity in Brain Development and Function. *Nat. Rev. Neurosci.* **2020**, *21*, 36–51. [[CrossRef](#)] [[PubMed](#)]
19. Yoon, K.-J.; Koo, B.-K.; Im, S.-K.; Jeong, H.-W.; Ghim, J.; Kwon, M.; Moon, J.-S.; Miyata, T.; Kong, Y.-Y. Mind Bomb 1-Expressing Intermediate Progenitors Generate Notch Signaling to Maintain Radial Glial Cells. *Neuron* **2008**, *58*, 519–531. [[CrossRef](#)] [[PubMed](#)]
20. Weng, Y.-L.; Wang, X.; An, R.; Cassin, J.; Vissers, C.; Liu, Y.; Liu, Y.; Xu, T.; Wang, X.; Wong, S.Z.H.; et al. Epitranscriptomic M6A Regulation of Axon Regeneration in the Adult Mammalian Nervous System. *Neuron* **2018**, *97*, 313–325.e6. [[CrossRef](#)]
21. Du, T.; Rao, S.; Wu, L.; Ye, N.; Liu, Z.; Hu, H.; Xiu, J.; Shen, Y.; Xu, Q. An Association Study of the M6A Genes with Major Depressive Disorder in Chinese Han Population. *J. Affect. Disord.* **2015**, *183*, 279–286. [[CrossRef](#)] [[PubMed](#)]
22. Shi, H.; Zhang, X.; Weng, Y.-L.; Lu, Z.; Liu, Y.; Lu, Z.; Li, J.; Hao, P.; Zhang, Y.; Zhang, F.; et al. M6A Facilitates Hippocampus-Dependent Learning and Memory through Ythdf1. *Nature* **2018**, *563*, 249–253. [[CrossRef](#)] [[PubMed](#)]
23. Li, L.; Zang, L.; Zhang, F.; Chen, J.; Shen, H.; Shu, L.; Liang, F.; Feng, C.; Chen, D.; Tao, H.; et al. Fat Mass and Obesity-Associated (FTO) Protein Regulates Adult Neurogenesis. *Hum. Mol. Genet.* **2017**, *26*, 2398–2411. [[CrossRef](#)]
24. Hess, M.E.; Hess, S.; Meyer, K.D.; Verhagen, L.A.W.; Koch, L.; Brönneke, H.S.; Dietrich, M.O.; Jordan, S.D.; Saletore, Y.; Elemento, O.; et al. The Fat Mass and Obesity Associated Gene (Fto) Regulates Activity of the Dopaminergic Midbrain Circuitry. *Nat. Neurosci.* **2013**, *16*, 1042–1048. [[CrossRef](#)]
25. Chen, X.; Yu, C.; Guo, M.; Zheng, X.; Ali, S.; Huang, H.; Zhang, L.; Wang, S.; Huang, Y.; Qie, S.; et al. Down-Regulation of M6A mRNA Methylation Is Involved in Dopaminergic Neuronal Death. *ACS Chem. Neurosci.* **2019**, *10*, 2355–2363. [[CrossRef](#)]
26. Chen, B.; Ye, F.; Yu, L.; Jia, G.; Huang, X.; Zhang, X.; Peng, S.; Chen, K.; Wang, M.; Gong, S.; et al. Development of Cell-Active N⁶-Methyladenosine RNA Demethylase FTO Inhibitor. *J. Am. Chem. Soc.* **2012**, *134*, 17963–17971. [[CrossRef](#)] [[PubMed](#)]
27. Aik, W.; Demetriades, M.; Hamdan, M.K.K.; Bagg, E.A.L.; Yeoh, K.K.; Lejeune, C.; Zhang, Z.; McDonough, M.A.; Schofield, C.J. Structural Basis for Inhibition of the Fat Mass and Obesity Associated Protein (FTO). *J. Med. Chem.* **2013**, *56*, 3680–3688. [[CrossRef](#)]
28. Zheng, G.; Cox, T.; Tribbey, L.; Wang, G.Z.; Jacoban, P.; Booher, M.E.; Gabriel, G.J.; Zhou, L.; Bae, N.; Rowles, J.; et al. Synthesis of a FTO Inhibitor with Anticonvulsant Activity. *ACS Chem. Neurosci.* **2014**, *5*, 658–665. [[CrossRef](#)]
29. Huang, Y.; Yan, J.; Li, Q.; Li, J.; Gong, S.; Zhou, H.; Gan, J.; Jiang, H.; Jia, G.-F.; Luo, C.; et al. Meclofenamic Acid Selectively Inhibits FTO Demethylation of M6A over ALKBH5. *Nucleic Acids Res.* **2015**, *43*, 373–384. [[CrossRef](#)]
30. Wang, X.; Zhao, B.S.; Roundtree, I.A.; Lu, Z.; Han, D.; Ma, H.; Weng, X.; Chen, K.; Shi, H.; He, C. N⁶-Methyladenosine Modulates Messenger RNA Translation Efficiency. *Cell* **2015**, *161*, 1388–1399. [[CrossRef](#)]
31. Huang, Y.; Su, R.; Sheng, Y.; Dong, L.; Dong, Z.; Xu, H.; Ni, T.; Zhang, Z.S.; Zhang, T.; Li, C.; et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. *Cancer Cell* **2019**, *35*, 677–691.e10. [[CrossRef](#)] [[PubMed](#)]
32. Karelson, M.; Selberg, S. Method of Suppressing Cancer by RNA M6A Demethylase AlkBH5 Inhibitors. WO2020207550, 15 October 2020.

33. Irwin, J.J.; Shoichet, B.K. ZINC—A Free Database of Commercially Available Compounds for Virtual Screening. *J. Chem. Inf. Model.* **2005**, *45*, 177–182. [[CrossRef](#)] [[PubMed](#)]
34. Bento, A.P.; Gaulton, A.; Hersey, A.; Bellis, L.J.; Chambers, J.; Davies, M.; Krüger, F.A.; Light, Y.; Mak, L.; McGlinchey, S.; et al. The ChEMBL Bioactivity Database: An Update. *Nucleic Acids Res.* **2014**, *42*, D1083–D1090. [[CrossRef](#)]
35. Zhang, X.; Wei, L.-H.; Wang, Y.; Xiao, Y.; Liu, J.; Zhang, W.; Yan, N.; Amu, G.; Tang, X.; Zhang, L.; et al. Structural Insights into FTO's Catalytic Mechanism for the Demethylation of Multiple RNA Substrates. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 2919–2924. [[CrossRef](#)] [[PubMed](#)]
36. Yu, L.-Y.; Jokitalo, E.; Sun, Y.-F.; Mehlen, P.; Lindholm, D.; Saarma, M.; Arumäe, U. GDNF-Deprived Sympathetic Neurons Die via a Novel Nonmitochondrial Pathway. *J. Cell Biol.* **2003**, *163*, 987–997. [[CrossRef](#)] [[PubMed](#)]
37. Lindholm, P.; Voutilainen, M.H.; Laurén, J.; Peränen, J.; Leppänen, V.-M.; Andressoo, J.-O.; Lindahl, M.; Janhunen, S.; Kalkkinen, N.; Timmusk, T.; et al. Novel Neurotrophic Factor CDNF Protects and Rescues Midbrain Dopamine Neurons in Vivo. *Nature* **2007**, *448*, 73–77. [[CrossRef](#)]
38. Yu, L.; Saarma, M.; Arumäe, U. Death Receptors and Caspases but Not Mitochondria Are Activated in the GDNF- or BDNF-Deprived Dopaminergic Neurons. *J. Neurosci.* **2008**, *28*, 7467–7475. [[CrossRef](#)]
39. Jasmin, M.; Ahn, E.H.; Voutilainen, M.H.; Fombonne, J.; Guix, C.; Viljakainen, T.; Kang, S.S.; Yu, L.; Saarma, M.; Mehlen, P.; et al. Netrin-1 and Its Receptor DCC Modulate Survival and Death of Dopamine Neurons and Parkinson's Disease Features. *EMBO J.* **2021**, *40*, e105537. [[CrossRef](#)]
40. Sidorova, Y.A.; Saarma, M. Can Growth Factors Cure Parkinson's Disease? *Trends Pharmacol. Sci.* **2020**, *41*, 909–922. [[CrossRef](#)]
41. Mauer, J.; Luo, X.; Blanjoie, A.; Jiao, X.; Grozhik, A.V.; Patil, D.P.; Linder, B.; Pickering, B.F.; Vasseur, J.-J.; Chen, Q.; et al. Reversible Methylation of m⁶A in the 5' Cap Controls mRNA Stability. *Nature* **2017**, *541*, 371–375. [[CrossRef](#)]
42. Mauer, J.; Sindelar, M.; Despica, V.; Guez, T.; Hawley, B.R.; Vasseur, J.-J.; Rentmeister, A.; Gross, S.S.; Pellizzoni, L.; Debart, F.; et al. FTO Controls Reversible m⁶A RNA Methylation during SnRNA Biogenesis. *Nat. Chem. Biol.* **2019**, *15*, 340–347. [[CrossRef](#)]
43. Wei, C.-M.; Gershowitz, A.; Moss, B. N⁶, O²'-Dimethyladenosine a Novel Methylated Ribonucleoside next to the 5' Terminal of Animal Cell and Virus MRNAs. *Nature* **1975**, *257*, 251–253. [[CrossRef](#)]
44. Gerken, T.; Girard, C.A.; Tung, Y.-C.L.; Webby, C.J.; Saudek, V.; Hewitson, K.S.; Yeo, G.S.H.; McDonough, M.A.; Cunliffe, S.; McNeill, L.A.; et al. The Obesity-Associated FTO Gene Encodes a 2-Oxoglutarate-Dependent Nucleic Acid Demethylase. *Science* **2007**, *318*, 1469–1472. [[CrossRef](#)]
45. Airaksinen, M.S.; Saarma, M. The GDNF Family: Signalling, Biological Functions and Therapeutic Value. *Nat. Rev. Neurosci.* **2002**, *3*, 383–394. [[CrossRef](#)] [[PubMed](#)]
46. Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and Ligand Preparation: Parameters, Protocols, and Influence on Virtual Screening Enrichments. *J. Comput. Aided Mol. Des.* **2013**, *27*, 221–234. [[CrossRef](#)]
47. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.;Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. *J. Comput. Chem.* **2009**, *30*, 2785–2791. [[CrossRef](#)] [[PubMed](#)]
48. Stephens, P.J.; Devlin, F.J.; Chabalowski, C.F.; Frisch, M.J. Ab Initio Calculation of Vibrational Absorption and Circular Dichroism Spectra Using Density Functional Force Fields. *J. Phys. Chem.* **1994**, *98*, 11623–11627. [[CrossRef](#)]
49. Bowers, K.J.; Chow, D.E.; Xu, H.; Dror, R.O.; Eastwood, M.P.; Gregersen, B.A.; Klepeis, J.L.; Kolossvary, I.; Moraes, M.A.; Sacerdoti, F.D.; et al. Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. In Proceedings of the 2006 ACM/IEEE Conference on Supercomputing (SC '06), Tampa, FL, USA, 11–17 November 2006; p. 43.
50. Banks, J.L.; Beard, H.S.; Cao, Y.; Cho, A.E.; Damm, W.; Farid, R.; Felts, A.K.; Halgren, T.A.; Mainz, D.T.; Maple, J.R.; et al. Integrated Modeling Program, Applied Chemical Theory (IMPACT). *J. Comput. Chem.* **2005**, *26*, 1752–1780. [[CrossRef](#)]
51. Toukmaji, A.Y.; Board, J.A. Ewald Summation Techniques in Perspective: A Survey. *Comput. Phys. Commun.* **1996**, *95*, 73–92. [[CrossRef](#)]
52. Zielkiewicz, J. Structural Properties of Water: Comparison of the SPC, SPCE, TIP4P, and TIP5P Models of Water. *J. Chem. Phys.* **2005**, *123*, 104501. [[CrossRef](#)]
53. McQuin, C.; Goodman, A.; Chernyshev, V.; Kamentsky, L.; Cimini, B.A.; Karhohs, K.W.; Doan, M.; Ding, L.; Rafelski, S.M.; Thirstrup, D.; et al. CellProfiler 3.0: Next-Generation Image Processing for Biology. *PLoS Biol.* **2018**, *16*, e2005970. [[CrossRef](#)]
54. Mahato, A.K.; Kopra, J.; Renko, J.-M.; Visnapuu, T.; Korhonen, I.; Pulkkinen, N.; Bessalov, M.M.; Domanskyi, A.; Ronken, E.; Piepponen, T.P.; et al. Glial Cell Line-Derived Neurotrophic Factor Receptor Rearranged During Transfection Agonist Supports Dopamine Neurons In Vitro and Enhances Dopamine Release In Vivo. *Mov. Disord.* **2020**, *35*, 245–255. [[CrossRef](#)]
55. Joncour, V.L.; Karaman, S.; Laakkonen, P.M. Predicting In Vivo Payloads Delivery Using a Blood-Brain Tumor-Barrier in a Dish. *J. Vis. Exp.* **2019**, e59384. [[CrossRef](#)] [[PubMed](#)]